Share

April 2022; 8 (2) Research ArticleOpen Access

Clinical-Genetic Features Influencing Disability in Spastic Paraplegia Type 4

A Cross-sectional Study by the Italian DAISY Network

Salvatore Rossi, Anna Rubegni, Vittorio Riso, Melissa Barghigiani, Maria Teresa Bassi, Roberta Battini, Enrico Bertini, Cristina Cereda, Ettore Cioffi, Chiara Criscuolo, Beatrice Dal Fabbro, Clemente Dato, Maria Grazia D'Angelo, Antonio Di Muzio, Luca Diamanti, Maria Teresa Dotti, Alessandro Filla, Valeria Gioiosa, Rocco Liguori, Andrea Martinuzzi, Roberto Massa, Andrea Mignarri, Rossana Moroni, Olimpia Musumeci, Francesco Nicita, Ilaria Orologio, Laura Orsi, Elena Pegoraro, Antonio Petrucci, Massimo Plumari, Ivana Ricca, Giovanni Rizzo, Silvia Romano, Roberto Rumore, Simone Sampaolo, Marina Scarlato, Marco Seri, Cristina Stefan, Giulia Straccia, Alessandra Tessa, Lorena Travaglini, Rosanna Trovato, Lucia Ulgheri, Giovanni Vazza, Antonio Orlacchio, Gabriella Silvestri, Filippo Maria Santorelli, Mariarosa Anna Beatrice Melone, Carlo Casali
First published March 30, 2022, DOI: https://doi.org/10.1212/NXG.0000000000000664
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
451

Share

Abstract

Background and Objectives Hereditary spastic paraplegias (HSPs) are a group of inherited rare neurologic disorders characterized by length-dependent degeneration of the corticospinal tracts and dorsal columns, whose prominent clinical feature is represented by spastic gait. Spastic paraplegia type 4 (SPG4, SPAST-HSP) is the most common form. We present both clinical and molecular findings of a large cohort of patients, with the aim of (1) defining the clinical spectrum of SPAST-HSP in Italy; (2) describing their molecular features; and (3) assessing genotype-phenotype correlations to identify features associated with worse disability.

Methods A cross-sectional retrospective study with molecular and clinical data collected in an anonymized database was performed.

Results A total of 723 Italian patients with SPAST-HSP (58% men) from 316 families, with a median age at onset of 35 years, were included. Penetrance was 97.8%, with men showing higher Spastic Paraplegia Rating Scale (SPRS) scores (19.67 ± 12.58 vs 16.15 ± 12.61, p = 0.009). In 26.6% of patients with SPAST-HSP, we observed a complicated phenotype, mainly including intellectual disability (8%), polyneuropathy (6.7%), and cognitive decline (6.5%). Late-onset cases seemed to progress more rapidly, and patients with a longer disease course displayed a more severe neurologic disability, with higher SPATAX (3.61 ± 1.46 vs 2.71 ± 1.20, p < 0.001) and SPRS scores (22.63 ± 11.81 vs 12.40 ± 8.83, p < 0.001). Overall, 186 different variants in the SPAST gene were recorded, of which 48 were novel. Patients with SPAST-HSP harboring missense variants displayed intellectual disability (14.5% vs 4.4%, p < 0.001) more frequently, whereas patients with truncating variants presented more commonly cognitive decline (9.7% vs 2.6%, p = 0.001), cerebral atrophy (11.2% vs 3.4%, p = 0.003), lower limb spasticity (61.5% vs 44.5%), urinary symptoms (50.0% vs 31.3%, p < 0.001), and sensorimotor polyneuropathy (11.1% vs 1.1%, p < 0.001). Increasing disease duration (DD) and abnormal motor evoked potentials (MEPs) were also associated with increased likelihood of worse disability (SPATAX score>3).

Discussion The SPAST-HSP phenotypic spectrum in Italian patients confirms a predominantly pure form of HSP with mild-to-moderate disability in 75% of cases, and slight prevalence of men, who appeared more severely affected. Early-onset cases with intellectual disability were more frequent among patients carrying missense SPAST variants, whereas patients with truncating variants showed a more complicated disease. Both longer DD and altered MEPs are associated with worse disability.

Glossary

AAA=
ATPases Associated with diverse cellular Activities;
AAE=
age at the last available examination;
AAO=
age at onset;
AD=
autosomal dominant;
DD=
disease duration;
HSP=
hereditary spastic paraplegia;
MEP=
motor evoked potential;
SPG=
spastic paraplegia gene;
SPG4=
SPG type 4;
SPRS=
Spastic Paraplegia Rating Scale;
SSEP=
somatosensory evoked potential;
TCC=
thin corpus callosum;
UL=
upper limb

Hereditary spastic paraplegias (HSPs) are a group of rare inherited neurologic disorders characterized by length-dependent degeneration of the corticospinal tracts and dorsal columns, with spastic gait being their prominent clinical feature.1,2 Globally, HSPs have a prevalence of 1–5/100,000 individuals worldwide.3 They can be inherited as autosomal dominant (AD), autosomal recessive, recessive X-linked, or mitochondrial traits, and current genetic classification relies on sequential numbering of loci or genes using a spastic paraplegia gene (SPG) designation.1 To our knowledge, 85 different disease loci have been identified in 79 known causative genes.4

The SPG type 4 (SPG4, also known as SPAST-HSP, OMIM #182601) is the most common form, accounting for about 40% of AD-HSPs and 20% of sporadic HSPs.3,5 SPAST-HSP has long been considered the prototype of pure HSP, yet other neurologic features may be also part of its phenotype.6 SPAST-HSP is caused by heterozygous variants in the SPAST gene (OMIM# 604277), encoding spastin, a protein of 616 amino acids that is a member of the ATPases Associated with diverse cellular Activities (AAA) protein family.6 The microtubule-severing activity represents the main function of spastin, which hydrolyzes adenosine tri-phosphate (ATP) to sever microtubules.7 Four isoforms of spastin are known, comprising the full-length protein (M1), a shorter isoform (M87) lacking the first 86 amino acids of the M1, and 2 splice variants of these, derived from the exclusion of the exon 4.8,9 Spastin shows a modular structure, including an N-terminal domain, a microtubule interacting and trafficking domain, a microtubule-binding domain, and an AAA ATPase cassette.10,11

More than 250 pathogenic variants of the SPAST gene have been reported, most of them located in the tripleA protein domain. Missense changes, mostly clustering in the AAA domain, represent the most frequent variants, followed by frameshift, splice site, nonsense variants and deletions, that have been found to be scattered throughout the whole gene.12

The characterization of large cohorts of patients with HSP usually offers a significant contribution to clinical research regarding rare disorders. Herein, we present clinical and molecular findings of 723 patients with SPAST-HSP gathered by several neurologic centers throughout Italy, with the aim of (1) defining the clinical spectrum of SPAST-HSP in Italy; (2) describing their molecular characteristics; and (3) assessing genotype-phenotype correlations to identify potential features associated with worse disease severity.

Methods

We retrospectively collected in an anonymized database both molecular and clinical cross-sectional data from a total of 723 Italian patients with SPAST-HSP from 316 families, referred to 23 Italian centers with a specific expertise on neurogenetic diseases from the Disease Alliance for Italian Spastic Paraplegia centered for You (DAISY) network. Only patients with confirmed molecular diagnosis of SPAST-HSP were included. Data were collected from July 2020 to December 2020. Eight pedigrees included in this study had been already described elsewhere.13,-,20 Strengthening the Reporting of Observational Studies in Epidemiology cross-sectional reporting guidelines were used.21

DNA Collection and Mutation Analysis

Blood samples were collected at each referral center for both diagnostic and research purposes, according to the protocols of the respective Institutional Ethical Committees, and sent for genomic DNA extraction from peripheral leukocytes and molecular analyses and/or confirmation to 1 of the 2 major diagnostic participating centers (IRCCS Fondazione Stella Maris, Pisa, and Ospedale Pediatrico Bambino Gesù, Rome). Targeted sequencing and Sanger sequencing were used to detect point mutations in SPAST. Multiplex ligation-dependent probe amplification analysis was used to identify large deletions and/or duplications.22 Due to the methods employed, it cannot exclude that deep intronic changes or less typical structural variants could have been missed.

Variant classification was based on the American College of Medical Genetics and Genomics published guidelines.23 To define the impact of missense variants on protein function, we used an in silico pipeline encompassing 19 prediction tools including Mutation Assessor,24 FATHMM,25 LRT,26 Deo-gen2,26 Eigen,27 Eigen PC,27 Sorting Intolerant From Tolerant (SIFT),28 SIFT4G,29 Provean,30 Minimum Viable Product,26 Revel,26 Primate AI,26 MetaSVM,26 MetalR,26 Genomic Evolutionary Rate Profiling,26 PolyPhen-2 HumDir,31 PolyPhen-2 HumVar,31 UMD Predictor,32 and CADD.33 Splicing variants and synonymous variants close to splicing sites were also tested using Human Splicing Finder 3.134 and NNSPLICE 0.9.35 We included variants with minor allele frequency <0.1% in the ExAC,36 gnomAD,37 1000 Genomes Project,38 and dbSNP39 databases. Nevertheless, synonymous, intronic and other noncoding variants were considered only if they have already been described as pathogenic in previous literature. Whenever possible, segregation of specific variants was performed in family members (affected and not affected).

Clinical Features

Both demographic and phenotypic data were retrospectively collected from medical records for each patient with SPAST-HSP. A multicenter electronic, standardized sheet was used to reduce sources of bias in data entry, that was performed on a shared anonymized database.

Medical history data included family history for the same disorder, age at the last available examination (AAE) (years), age at onset (AAO) (years), and symptom of onset of SPAST-HSP. Findings of brain and spinal cord MRI, nerve conduction studies, and motor evoked (MEP) and somatosensory evoked potentials (SSEP) were recorded. Finally, current use of symptomatic antispastic drugs was also detailed. Overall penetrance was assessed by dividing the number of symptomatic patients by the total number of SPAST pathogenic variants' carriers.

Patients were classified as early- or late-onset forms if their AAO was below or above 10 years, respectively. Disease duration (DD) was calculated as AAE-AAO (years). Patients were divided into 2 groups (short- or long-lasting disease forms), using the median value of DD as threshold.

Pure forms were defined for patients manifesting signs of spastic paraplegia, characterized by pyramidal signs and weakness in the LL, and sphincter involvement and/or decreased sense of vibration at the ankles as additional features. Complex phenotype was defined for patients manifesting spastic paraplegia plus at least one other symptom, which could not be otherwise explained, including polyneuropathy, cerebellar ataxia, dysarthria, intellectual disability, parkinsonism, and cognitive decline. Patients were considered affected by cognitive decline if scored below 24 at Mini-Mental State Examination. Intellectual disability was defined if either children scored <70 at Wechsler Intelligence Scale for Children IV or they were delayed at Gross Motor Function Classification System or if they needed support while in school. Pes cavus, presence of Hoffmann sign, and/or brisk deep tendon reflexes in the upper limbs (UL) were considered as part of the pure phenotype, if not accompanied by muscle wasting.2,40 Disease severity was assessed using the Spastic Paraplegia Rating Scale (SPRS)41 and disease disability using the SPATAX disability score.12,42

Because of the cross-sectional study design, we estimated the rate of disease progression by the disability progression index (current SPATAX disability score divided by DD) and the disease progression index (current SPRS score divided by DD).43 For patients with available disease progression index values, tertiles were used to identify 3 groups: rapidly, typically, and slowly progressing forms.

To assess whether there was a significant reduction of AAO in subsequent generations, families with at least 2 affected members in the context of longitudinal transmission and with established AAO were included. A pseudo-longitudinal assessment of disease progression was possible in a subset of patients with multiple evaluations and SPRS scores.

Statistical Analysis

The sample was characterized in its clinical and demographic features using descriptive statistics techniques. Quantitative variables were described using mean and SD. Qualitative variables were summarized with absolute and percentage frequency tables. Normality of continuous variables was checked using the Kolmogorov-Smirnov test. One-way analysis of variance (ANOVA) was performed to compare AAO among the generations. N-value was specified for each variable. Patients with some missing values have been included in the study and maintained as missing.

The Mann-Whitney U test was used to evaluate the presence of any associations between specific features and various SPAST-HSP groups of patients (males/females, probands/family members, early-onset/late-onset cases, short-/long-DD cases, and missense variant carriers/truncating-variant carriers). The Kruskal-Wallis test with pairwise comparisons was used to compare qualitative variables when >2 subgroups of patients were analyzed (slowly vs typically vs rapidly progressing cases). The χ2 test (or Fisher 2-tailed exact test when required) was used to compare categorical variables between the groups. A logistic regression was performed to identify any factors associated with worse disability (identified by SPATAX score >3) or worse disease severity (SPRS score ≥26). Significance level was set at p < 0.05. Statistical analysis was performed by SPSS (Statistical Package for Social Science, IBM SPSS Statistics, Version 24.0. Armonk, NY: IBM Corp).

Standard Protocol Approvals and Patient Consents

The study was conducted according to the criteria set by the Declaration of Helsinki, and each patient or family member, in case of minors, signed an informed consent. The study protocol was approved by the Ethical Committee of the Fondazione Policlinico Universitario A. Gemelli IRCCS (Ethical Board approving number: ID 3998).

Data Availability

Anonymized patients' data are available on reasonable request.

Results

AAO, Clinical Signs, Disease Severity, and Diagnostic Findings

Clinical and demographic characteristics of the DAISY cohort are detailed in Tables 1 and 2. The whole cohort included 723 patients with SPAST-HSP (419 men, 58%) (Table 1) from 316 families, with a male-to-female ratio of 1.38. AAO was reported for 634 symptomatic patients, and it ranged from 0 to 80 years, with a mean age of 32.46 ± 17.41 years and a median of 35 years; the mean AAO was similar in the cohort including only the SPAST-HSP index cases (285/634, 44.95%, 31.91 ± 18.25 years), and it did not differ from the mean AAO of their affected relatives (349/634, 55.05%, 32.91 ± 16.72 years, p = 0.793) (eTable 1, links.lww.com/NXG/A516). The AAO followed a bimodal distribution (Figure 1), with the first peak observed in the first decade and the second between the fourth and the fifth decades. Fewer cases (13.1%, 83/634) had AAO ≤8 years.

View this table:
Table 1

Demographic, Clinical, Diagnostic, and Molecular Findings of the Whole SPAST–Hereditary Spastic Paraplegias Cohort

View this table:
Table 2

Age at Onset, Age at Examination, Disease Duration, and Severity Scales

Figure 1
Figure 1 Histogram Showing the Distribution of Age at Onset in the Study Cohort (n = 634)

Considering only families with at least 2 affected relatives from different generations (n = 46), the mean AAO was 39.77 ± 15.7 years (n = 56, median 41.5 years) in the first generation, 25.7 ± 15.6 years (n = 69, median 30 years) in the second generation, and 21.18 ± 15.3 years (n = 28, median 20.5 years) in the third generation. Such differences resulted statistically significant (p < 0.0005) by ANOVA (eFigure 1, links.lww.com/NXG/A516). Penetrance of the disease was 97.8%, with complete penetrance at age 80 years (Table 1).

The mean AAE (n = 631) was 45.25 ± 17.70 (range 2–95, median 47) years. AAO and AAE were both available for 599 patients, and the resulting mean DD was 12.87 ± 13.68 (range 0–64, median 7) years (Table 2). Regarding symptoms of onset, the most common presentation was gait difficulties (90.9%), followed by delayed motor milestones (6.7%) and sphincter disturbances (1.3%) (Table 1).

Most common clinical neurologic features included LL hyperreflexia (93.9%), spastic gait (93.9%) and Babinski sign (71.9%), then LL rest spasticity (57.1%), LL proximal weakness (54.2%), and urinary disturbances (43.7%), either presenting as urgency (28.7% of cases), incontinence (13.1%), frequency (3.7%), and/or dysuria (1.8%). Decreased vibration sense at ankles, pes cavus, UL hyperreflexia, Hoffmann sign, and gaze-evoked nystagmus occurred less frequently (Table 1, Figure 2).

Figure 2
Figure 2 Frequency of Neurologic Features in the Whole SPAST-Hereditary Spastic Paraplegias Cohort

In 26.6% of patients with SPAST-HSP (177/665), we observed a complicated phenotype: the most common associated features were intellectual disability (8%), cognitive decline (6.5%), and polyneuropathy (6.7%); other neurologic manifestations, including tremor, parkinsonism, distal muscle wasting, ataxia, and/or epilepsy, were variably present only in a minority of the SPAST-HSP cases (overall 6.9%) (Table 1). In most patients, we assume that the complicating features were related to the underlying SPAST variant, as we excluded the most common concurrent diseases (i.e., diabetes in case of polyneuropathy). However, we could not exclude that some rarer associated conditions explaining the complex phenotype, especially in singletons, might have been overlooked.

The mean SPATAX disability score was 3.15 ± 1.59 (n = 393), and the mean SPRS score was 18.22 ± 12.69 (n = 339), respectively (Table 2, Figure 3). Most of the patients with SPAST-HSP assessed by SPATAX had either moderate (SPATAX score = 3–5, 209/393, 53.18%) or mild (SPATAX score = 0–2, 142/393, 36.13%) functional impairment, and about 11% of them (42/393) manifested with a very severe motor disability (SPATAX score 6 and 7), causing loss of ambulatory capacity.

Figure 3
Figure 3 Histogram Showing the Distribution of the SPRS Score in the Study Cohort (n = 339)

Marked vertical black line shows the mean value, whereas red lines represent standard deviation values. SPRS = Spastic Paraplegia Rating Scale.

Data regarding therapy were available for 487 patients and documented that 66.7% of them assumed at least one of the following antispastic therapies: baclofen (8.1%), botulinum toxin (13.5%), tizanidine (11.7%), eperisone (2.2%), cannabinoids (2.2%), pregabalin/gabapentin (1.2%), and/or benzodiazepines (0.6%) (Table 1). The subjective impression on the efficacy of drug therapies was not recorded in our multicenter proforma sheet.

Globally, 20.0% of the patients with SPAST-HSP who underwent at least 1 brain MRI showed some alterations: some degree of cerebral atrophy was reported in 8.1% of cases and aspecific white matter hyperintensities in 6.3% of cases, whereas cerebellar atrophy and thin corpus callosum (TCC) were observed in 1.4% of cases each. Only 13 of 420 patients (3.1%) showed mild to moderate spinal cord atrophy at MRI (Table 1). Of note, peculiar brain MRI findings included 2 distinct complicated SPAST-HSP pedigrees previously reported. In the first family, all the affected carriers (c.1841C>T/p.T614I) showed a congenital pontocerebellar arachnoid cyst,15 whereas in the second (c.961dupG/p.D321Gfs*6), all patients with SPAST-HSP had signs of frontotemporal atrophy associated with temporal lobe epilepsy.17

Peripheral nerve involvement was reported only in 6.7% of patients with SPAST-HSP (31 of 466), mainly with features of sensory-motor axonal polyneuropathy. MEP displayed impaired central conduction time in 73.9% of examined patients, whereas SSEP revealed altered central sensory pathway conduction in 18.2% of cases (Table 1).

Sex Differences and Factors Associated With AAO, Severity, and Progression of the Disease

In our cohort, males with SPAST-HSP showed more frequently spastic gait (96.6%, 373/386 vs 90.1%, 246/273, p = 0.001) and higher SPRS score (19.67 ± 12.58 vs 16.15 ± 12.61, p = 0.009, eFigure 2, eTable 2). Antispastic treatments also resulted more frequent among male compared with female patients (71.6%, 204/285 vs 59.9%, 121/202, p = 0.007) (eTable 2). Any of these sex differences neither depended on the AAO (32.75 ± 17.11 vs 32.04 ± 17.87, p = 0.855) nor on the DD (12.98 ± 13.38 vs 12.70 ± 14.15, p = 0.307). Penetrance was also slightly higher in males, yet not reaching the statistical significant values (98.8%, 396/401 vs 96.6%, 280/290, p = 0.064) (eTable 2).

To assess if AAO could influence the severity of the neurologic phenotype, we divided the whole SPAST-HSP cohort in early (≤10 years-old) and late-onset (>10 years-old) cases according to the age of patients at their initial symptoms. Both neurologic disability and disease severity, assessed by SPATAX and by SPRS scores, respectively, were similar in the 2 groups (eTable 3, links.lww.com/NXG/A516); however, late-onset cases seemed to progress more rapidly. This observation is supported by both their higher disability progression (0.38 ± 0.49 vs 0.26 ± 0.27, p = 0.014) and disease progression indices (1.87 ± 2.13 vs 1.18 ± 1.18, p < 0.001) (eTable 3). Moreover, late-onset patients were more likely undergoing antispastic treatment (72.2% vs 39.4%, p < 0.001) (eTable 3).

Conversely, early-onset cases more often presented with complicated forms (46% vs 24.8%, p < 0.001) and mainly associated with intellectual disability (35.6% vs 3.4%, p < 0.001) (eTable 3, links.lww.com/NXG/A516). Moreover, missense variants were more frequent among early-onset cases (56.7% vs 40.7%, p = 0.005).

Patients with SPAST-HSP were also compared according to their DD, and the median value of 7 years was the cutoff to classify them into short- and long-duration cases, respectively. Long-DD SPAST-HSP patients displayed a more severe neurologic disability, with higher SPATAX (3.61 ± 1.46, n = 252 vs 2.71 ± 1.20, n = 91, p < 0.001) and SPRS scores (22.63 ± 11.81, n = 211 vs 12.40 ± 8.83, n = 73, p < 0.001), and as expected, they had a lower AAO (29.39 ± 17.32, n = 294 vs 36.15 ± 17.04, n = 299, p < 0.001) (eTable 4, links.lww.com/NXG/A516). Of interest, they were also more frequently carriers of truncating variants (63.1%, 154/244 vs 51.2%, 144/281, p = 0.006) and showed more often associated signs of UL involvement (eTable 4). Finally, long-DD SPAST-HSP patients more frequently displayed MRI alterations and cognitive decline (eTable 4).

Based on tertiles of the values of disease progression index (0.83 and 1.7 points/y), available for 278 patients, we identified the group of slowly (≤0.83 points/y), typically (>0.83 and ≤1.7 points/y), and rapidly evolving (>1.7 points/y) patients with SPAST-HSP (eTable 5, links.lww.com/NXG/A516). Rapidly evolving patients had later AAO (38.91 ± 18.88 years vs 32.94 ± 16.61 years in typically evolving patients and 23.09 ± 17.52 years in slowly progressing patients, p < 0.0005), more often displayed impaired central MEPs (62.3% vs 43.6% in typically evolving vs 34.0% in slowly progressing patients, p = 0.012), and more frequently were complicated forms (36.7% vs 16.2% in typically evolving vs 12.6% in slowly progressing patients, p < 0.0005). No substantial differences regarding class of SPAST-HSP pathogenic variant were found between slowly and rapidly evolving SPAST-HSP cases in our cohort (eTable 5).

Type and Distribution of Variants and Genotype-Phenotype Correlations

Overall, 186 different variants in SPAST were recorded among 316 SPAST-HSP families included in this study (Figure 4). Forty-eight variants (25.8%) have not been reported elsewhere, and 8 of 186 were present in the gnomAD polymorphic database, though all at a very low frequency (<0.1%) (eTable 6, links.lww.com/NXG/A516). The most common types were missense (41.40%, 77/186), followed by frameshift (20.43%, 38/186), deletions (14.52%, 27/186), nonsense (13.98%, 26/186), splice site (8.06%, 15/186), and duplications (1.61%, 3/186). Most of the missense variants (87.01%, n = 67/77) clustered in the AAA domain, between amino acids 342 and 599.

Figure 4
Figure 4 Schematic Representation of the Molecular Data

The pie chart (A) illustrates the relative prevalence of different variants found (total number: 186). The histogram (B) schematizes their relative prevalence in the whole SPAST-HSP cohort (n = 710).

The c.131C>T/p.S44L, previously reported as a modifier sequence variation,64 was reported in a single male individual with symptom onset at the age of 45 years, who manifested a moderately severe disease (SPRS of 23 after 12 years of disease) and showed an associated cognitive decline. This patient harbored the c.1634C>G/p.S545* on the other allele. Of interest, the 131C>T/p.S44L sequence variation was the unique variant detected in a 84-year old woman displaying a very-late-onset (74 years) spastic paraparesis, associated with TCC and signs of cerebellar atrophy at the brain MRI. However, we did not include her in the study cohort, as pathogenic SPAST variants were not found in association with such modifier.

The prevalence of individual neurological manifestations was compared between SPAST-HSP carriers of truncating (namely frameshift, nonsense, splice site, and small deletions) vs missense variants (eTable 7, links.lww.com/NXG/A516).

Carriers of missense and truncating changes did not differ regarding the AAO (eTable 7, links.lww.com/NXG/A516). Patients with SPAST-HSP with missense variants had shorter DD (10.16 ± 12.34, n = 227 vs 14.31 ± 14.54, n = 298, p < 0.001), but higher SPATAX score (3.56 ± 1.69, n = 114 vs 3.05 ± 1.49, n = 204, p = 0.009, eTable 7). Also, they displayed more frequently intellectual disability (14.5%, 34/243 vs 4.4%, 13/297, p < 0.001) (eTable 7).

Conversely, patients with truncating variants more commonly presented cognitive decline (9.7%, 29/299 vs 2.6%, 6/232, p = 0.001) and showed cerebral atrophy at the brain MRI (11.2%, 29/259 vs 3.4%, 6/178, p = 0.003) (eTable 7, links.lww.com/NXG/A516). Moreover, they more frequently had LL spasticity at rest (61.5%, 198/322 vs 44.5%, 106/238, p < 0.001), LL proximal weakness (59.6%, 190/319 vs 44.1%, 105/238, p < 0.001), urinary symptoms (50.0%, 157/314 vs 31.3%, 73/233, p < 0.001), polyneuropathy (11.1%, 25/226 vs 1.1%, 2/177, p < 0.001) and pes cavus (36.1%, 110/305 vs 23.1%, 54/234, p = 0.001) (eTable 7, links.lww.com/NXG/A516).

Factors Associated With Worse Disability and Disease Severity

A binomial logistic regression was performed to ascertain the effects of DD, phenotype (pure or complicated), presence of altered MEPs, intellectual disability or cognitive impairment, and class of variant on the likelihood that patients had worse disability (SPATAX score >3). The logistic regression model was statistically significant, χ2(2) = 31689, p < 0.0005. The model explained 19.8% (Nagelkerke R2) of the variance in SPATAX and correctly classified 64.0% of cases. Sensitivity was 46.3%, and specificity was 76.3%. Of the 6 predictor variables, only 2 were statistically significant: DD and impaired MEPs (as shown in Table 3). Increasing DD was associated with an increased likelihood of exhibiting SPATAX>3. Patients with increased central motor conduction time at MEPs had 2.72 times higher odds to exhibit a SPATAX score >3 than patients with normal MEPs. Longer DD was also associated with an increased likelihood of exhibiting a worse disease severity, i.e., SPRS ≥26 (eTable 8, links.lww.com/NXG/A516).

View this table:
Table 3

Binomial Logistic Regression to Identify Variables Associated With SPATAX Score >3

Pseudo-longitudinal assessment of disease progression was feasible in 28 patients from 16 families in whom more than 4 clinical evaluation and SPRS scoring were possible over on average a 3.4 ± 2.2 year period. Median disease progression was 0.5 (range −1 to −6.35, mean 0.78 ± 1.40) point/yr.

Discussion

This study provides a detailed clinical and genetic characterization of a wide Italian SPAST-HSP cohort, which, to our knowledge, is one of the largest cohorts reported.12,40,44,45 This work represents the first achievement of the DAISY network, created to support collaborative research on HSPs in Italy. Our data confirm a predominant association of SPAST-HSP with pure HSP forms,12 often characterized by mild or moderate motor disability, supporting the relatively benign course of SPAST-HSP when compared with other HSPs.1

In patients with SPAST-HSP manifesting with complicated forms, peripheral nerve and/or cognitive involvement were prevalently associated with spasticity: in this regard, our SPAST-HSP cohort shows a mildly higher prevalence of cognitive involvement than others,12,40,45,46 whereas psychiatric manifestations were rare. Our findings are supported by the results of a small cross-sectional study assessing cognitive involvement in SPAST-HSP, evidencing signs of cognitive impairment in more than 80% of the 31 adults and low average IQ scores in 60% of the 5 children tested.47

Regarding potential neuroanatomic correlates of cognitive involvement in SPAST-HSP, routine brain MRI is often normal,48,49 with peculiar abnormalities anecdotically reported only in some families.50,-,52 In our cohort, similar to what previously reported,45 signs of cortical atrophy and/or WMH were detected in about 20% of patients with available brain MRI data. Nonetheless, more advanced MRI techniques have allowed to reveal widespread signs of CNS involvement also in patients with SPAST-HSP,53,54 and accordingly data from a knock-down zebrafish SPAST-HSP model support a role for spastin on maintenance not only of the longest central axons but also of other CNS pathways.55 Advanced neuroimaging studies on larger patients' cohorts using standardized protocols are needed to better define the pattern of brain involvement in SPAST-HSP and the functional role of spastin in the CNS.

As in previous similar studies, we observed and documented an age-related penetrance and a bimodal distribution regarding AAO in our SPAST-HSP cohort too,12,44,45,56 with 1 peak in the first decade and the second during mid-adulthood. However, the mean AAO of our patients (about 32 years) was slightly higher compared with other SPAST-HSP cohorts,12,40,46,57,-,59 likely because the DAISY network mostly involves neurologic centers for adult patients (19/23 centers).

Moreover, as already observed by some authors,40,56 we assessed a pseudo-anticipation of parental transmission in some SPAST-HSP pedigrees included in our study. This might actually result from earlier detection of clinical HSP signs in children of adult probands assessed for genetic counseling. Yet, the occurrence of pseudo-anticipation has been proposed in other genetic disorders not caused by microsatellite expansions, possibly due to still unknown genetic or epigenetic mechanisms.60 Therefore, we are planning to conduct prospective studies on available large SPAST-HSP pedigrees with affected probands of 2 or more generations to definitely clarify this issue.

Differently from previous studies documenting either a slight male excess12 or no specific sex prevalence,44 we found a definite higher male prevalence in our SPAST-HSP cohort (M:F ratio ∼1.4). Two systematic literature reviews59,61 also indicated a higher male prevalence in SPAST-HSP, supporting our findings. Furthermore, our SPAST-HSP male group manifested worse motor disability, i.e., showed higher mean SPRS score and more frequent use of antispastic drugs compared with the female group. These findings might support a protective effect of estrogens in female carriers of SPAST pathogenic variants, as proposed by some authors,61 and, in our opinion, this topic should be further addressed in experimental SPAST-HSP models.

According to the literature,12,40,44 our study confirmed that longer duration and faster disease progression were both associated with worse functional motor outcome; of further note, pathologic MEP responses were also associated with worse motor disability, suggesting the potential role of MEPs as prognostic predictor in SPAST-HSP. A recent systematic review about MEP studies in HSPs62 confirmed a similar prevalence of MEP abnormalities in patients with SPAST-HSP (∼60%–70% vs 74% of our cohort), but it could not draw definite conclusions about their prognostic role. In this regard, longitudinal studies on large patients' cohorts could help to definitively address the prognostic value of MEPs in SPAST-HSP.

By comparing early- and late-onset SPAST-HSP forms within our cohort, both groups showed a similar disease burden, as we did not find differences regarding either degree of disability or global disease severity. These findings are in contrast with those obtained in a large French-German SPAST-HSP cohort12 and, conversely, agree with those obtained in another research study40: such discrepancies could be either related to different criteria used to classify early and late-onset forms40 or to a bias due to the retrospective design of the studies.12,40

Revision of genetic data evidenced 186 distinct SPAST pathogenic variants in our families, of which 48 have never been reported. As in other SPAST-HSP cohorts, we found predominance of truncating variants12,40,45,58,63 and overall comparable frequency of missense pathogenic variants.40,45

In one of our patient with SPAST-HSP, we also found the heterozygous S44L (p.Ser44Leu) variant, a known genetic modifier in SPAST-HSP, in association with a pathogenic SPAST variant. This specific variant, with an allele frequency between 0.6%64 and 3.1%65 in controls, was reported to negatively affect AAO and/or disease severity when associated with pathogenic SPAST variants, likely by downregulating the expression of the M87 isoform or increasing the stability of the M1 isoform.6,64 Of interest, a patient with sporadic pure HSP not included in this SPAST-HSP cohort, who had a very late symptom onset, only resulted carrier of the heterozygous S44L at SPAST molecular testing. It is debated whether the S44L might play per se a detrimental role on upper motor neurons function under specific conditions.45 However, given the evidence of age-related penetrance of SPAST-HSP pathogenic variants, this case suggests that it could also exert a milder yet detrimental effect on the longest pyramidal axons manifesting only at a very advanced age.

Genotype-phenotype correlations confirmed that intellectual disability was more frequent among carriers of SPAST missense variants,12 but instead, no associations were found with disease severity. The association of missense SPAST variants with both early-onset cases and the occurrence of intellectual disability in SPAST-HSP suggests that these class of pathogenic variants might affect brain development possibly through a dominant negative gain of function.7 Indeed, microtubule-severing spastin activity is also relevant during neurodevelopment.6

On the other hand, signs or symptoms of a more widespread neurologic involvement, such as polyneuropathy, cognitive decline and/or cerebral atrophy, were more frequently associated with truncating variants, supporting that reduced levels of spastin expression could also affect other pathways besides the dorsal columns and corticospinal axons.40

The main limitation of our study consists in the retrospective and largely cross-sectional design, which might have yielded bias in data collection. Some data, as approximation of penetrance, unquestionably need more accurate family studies to be clearly established. Moreover, some discrepancies between our results and those of previous similar retrospective studies on SPAST-HSP might depend either on the differences in the sample size or in the applied diagnostic protocols.

In conclusion, we have characterized in detail the clinical and molecular spectrum of a wide Italian cohort of patients with SPAST-HSP, being among the largest described in the literature. Our results point out to DD, evidence of MEP alterations, and possibly male sex, as predictors of worse disability.

A recent study involving both animal- and patient-derived SPAST-HSP neuronal cell models supported the feasibility of spastin-elevating therapeutic approaches to rescue neurite defects8,66: thus, the establishment of this Italian network will hopefully carry on contributing in the HSP research field sharing large patients' cohorts for further collaborative studies aiming to assess reliable biomarkers of disease severity and/or progression in SPAST-HSP, a still unmet need in view of forthcoming clinical trials to test disease-modifying therapies.

Study Funding

S.R. received a fellowship partially funded by Associazione Italiana Vivere la Paraparesi Spastica (A.I.Vi.P.S) Onlus. This work was supported by the Italian Ministry of Health (Grant no. RF19.12 to A.O.) and the Department of Medicine and Surgery of the University of Perugia (Fondo Ricerca di Base, Grants no. DSCH_BASE19_ORLACCHIO and DMCH_BASE20_ORLACCHIO to A.O) and by funds from the Italian Ministry of Health, grant RC2021 (to FMS), and RC2021, grant RF-2019-12370112, and from the Fondazione Regionale Lombarda per la Ricerca Biomedica (FRRB) RC2021 (to FMS); grant Care4Neurorare (to MTB), and Italian Ministry of Scientific Research, Linea D1 2020 (to GS).

Disclosure

The authors report no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Acknowledgment

The authors thank the Associazione Italiana Vivere la Paraparesi Spastica (A.I.Vi.P.S) Onlus for supporting the redaction of this manuscript and for promoting HSP research. They deeply thank all the patients with SPAST-HSP and their families who contributed to this work because their support and dedication to science fully repays all our efforts. F.N. and E.B. are members of the European Reference Network for Rare Neurological Diseases. They thank Dr. Isabella Miele for revising the English form of the manuscript.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NG for full disclosures. Full information is provided at the end of the article.

  • ↵* These authors contributed equally to this work.

  • The Article Processing Charge was funded by the Fondazione Policlinico A. Gemelli IRCCS.

  • Received October 13, 2021.
  • Accepted in final form January 31, 2022.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Shribman S,
    2. Reid E,
    3. Crosby AH,
    4. Houlden H,
    5. Warner TT
    . Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurol. 2019;18(12):1136-1146.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Harding AE
    . Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1(8334):1151-1155.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ruano L,
    2. Melo C,
    3. Silva MC,
    4. Coutinho P
    . The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174-183.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bellofatto M,
    2. De Michele G,
    3. Iovino A,
    4. Filla A,
    5. Santorelli FM
    . Management of hereditary spastic paraplegia: a systematic review of the literature. Front Neurol. 2019, 10;3.
    OpenUrl
  5. 5.↵
    1. Lo Giudice T,
    2. Lombardi F,
    3. Santorelli FM,
    4. Kawarai T,
    5. Orlacchio A
    . Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol. 2014;261:518-539.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Solowska JM,
    2. Baas PW
    . Hereditary spastic paraplegia SPG4: what is known and not known about the disease. Brain. 2015;138(pt 9):2471-2484.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Errico A,
    2. Ballabio A,
    3. Rugarli EI
    . Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. Hum Mol Genet. 2002;11(2):153-163.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Havlicek S,
    2. Kohl Z,
    3. Mishra HK, et al.
    Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients' neurons. Hum Mol Genet. 2014;23(10):2527-2541.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Solowska JM,
    2. Garbern JY,
    3. Baas PW
    . Evaluation of loss of function as an explanation for SPG4-based hereditary spastic paraplegia. Hum Mol Genet. 2010;19(14):2767-2779.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Sandate CR,
    2. Szyk A,
    3. Zehr EA,
    4. Lander GC,
    5. Roll-Mecak A
    . An allosteric network in spastin couples multiple activities required for microtubule severing. Nat Struct Mol Biol. 2019;26(8):671-678.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Park SH,
    2. Zhu PP,
    3. Parker RL,
    4. Blackstone C
    . Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. J Clin Invest. 2010;120(4):1097-1110.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Parodi L,
    2. Fenu S,
    3. Barbier M, et al
    . Spastic paraplegia due to SPAST mutations is modified by the underlying mutation and sex. Brain. 2018;141(12):3331-3342.
    OpenUrlPubMed
  13. 13.↵
    1. Kawarai T,
    2. Montecchiani C,
    3. Miyamoto R, et al
    . Spastic paraplegia type 4: a novel SPAST splice site donor mutation and expansion of the phenotype variability. J Neurol Sci. 2017;380:92-97.
    OpenUrl
  14. 14.↵
    1. Orlacchio A,
    2. Patrono C,
    3. Borreca A,
    4. Babalini C,
    5. Bernardi G,
    6. Kawarai T
    . Spastic paraplegia in Romania: high prevalence of SPG4 mutations. J Neurol Neurosurg Psychiatry. 2008;79(5):606-607.
    OpenUrlFREE Full Text
  15. 15.↵
    1. Orlacchio A,
    2. Gaudiello F,
    3. Totaro A, et al
    . A new SPG4 mutation in a variant form of spastic paraplegia with congenital arachnoid cysts. Neurology. 2004;62(10):1875-1878.
    OpenUrl
  16. 16.↵
    1. Orlacchio A,
    2. Kawarai T,
    3. Gaudiello F, et al
    . Clinical and genetic study of a large SPG4 Italian family. Mov Disord. 2005;20(8):1055-1059.
    OpenUrlPubMed
  17. 17.↵
    1. Orlacchio A,
    2. Patrono C,
    3. Gaudiello F, et al
    . Silver syndrome variant of hereditary spastic paraplegia: a locus to 4p and allelism with SPG4. Neurology. 2008;70(21):1959-1966.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Racis L,
    2. Di Fabio R,
    3. Tessa A, et al
    . Large deletion mutation of SPAST in a multi-generation family from Sardinia. Eur J Neurol. 2014;21(6):935-938.
    OpenUrl
  19. 19.↵
    1. Santorelli FM,
    2. Patrono C,
    3. Fortini D, et al
    . Intrafamilial variability in hereditary spastic paraplegia associated with an SPG4 gene mutation. Neurology. 2000;55(5):702-705.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Scarlato M,
    2. Nuara A,
    3. Gerevini S, et al
    . A new double-trouble phenotype: fascioscapulohumeral muscular dystrophy ameliorates hereditary spastic paraparesis due to spastin mutation. J Neurol. 2015;262(2):476-478.
    OpenUrl
  21. 21.↵
    1. von Elm E,
    2. Altman DG,
    3. Egger M,
    4. Pocock SJ,
    5. Gøtzsche PC,
    6. Vandenbroucke JP
    . Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808.
    OpenUrlFREE Full Text
  22. 22.↵
    1. Shoukier M,
    2. Neesen J,
    3. Sauter SM, et al
    . Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia. Eur J Hum Genet. 2009;17(2):187-194.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Richards S,
    2. Aziz N,
    3. Bale S, et al
    . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405-424.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Mutation Assessor. Accessed August 31, 2021. mutationassessor.org/r3/
  25. 25.↵
    FATHMM. Accessed August 21, 2021. fathmm.biocompute.org.uk/
  26. 26.↵
    Varsome. Accessed August 21, 2021. varsome.com/
  27. 27.↵
    Eigen. Accessed August 21, 2021. columbia.edu/∼ii2135/eigen.html/
  28. 28.↵
    SIFT. Accessed August 21, 2021. sift.bii.a-star.edu.sg/
  29. 29.↵
    SIFT4G. Accessed August 21, 2021. sift.bii.astar.edu.sg/sift4g/
  30. 30.↵
    Provean. Accessed August 21, 2021. provean.jcvi.org/index.php/
  31. 31.↵
    PolyPhen-2 HumVar. Accessed August 21, 2021. genetics.bwh.harvard.edu/pph2/
  32. 32.↵
    UMD Predictor. Accessed August 21, 2021. umd-predictor.eu/
  33. 33.↵
    CADD. Accessed August 21, 2021. cadd.gs.washington.edu/
  34. 34.↵
    Human Splicing Finder 3.1. Accessed August 21, 2021. umd.be/HSF/
  35. 35.↵
    NNSPLICE 0.9. Accessed August 21, 2021. fruitfly.org/seq_tools/splice.html/
  36. 36.↵
    ExAC. Accessed August 21, 2021. exac.broadinstitute.org/
  37. 37.↵
    gnomAD. Accessed August 21, 2021. gnomad.broadinstitute.org/
  38. 38.↵
    1000 Genomes Project. Accessed August 21, 2021. internationalgenome.org/
  39. 39.↵
    dbSNP databases. Accessed August 21, 2021. ncbi.nlm.nih.gov/snp/
  40. 40.↵
    1. Chelban V,
    2. Tucci A,
    3. Lynch DS, et al
    . Truncating mutations in SPAST patients are associated with a high rate of psychiatric comorbidities in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry. 2017;88(8):681-687.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Schüle R,
    2. Holland-Letz T,
    3. Klimpe S, et al
    . The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity. Neurology. 2006;67(3):430-434.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Chrestian N,
    2. Dupré N,
    3. Gan-Or Z, et al
    . Clinical and genetic study of hereditary spastic paraplegia in Canada. Neurol Genet. 2017;3(1):e122.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Wilke C,
    2. Rattay TW,
    3. Hengel H, et al
    . Serum neurofilament light chain is increased in hereditary spastic paraplegias. Ann Clin Transl Neurol. 2018;5(7):876-882.
    OpenUrl
  44. 44.↵
    1. Schüle R,
    2. Wiethoff S,
    3. Martus P, et al.
    Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients: hereditary spastic paraplegia. Ann Neurol. 2016;79(4):646-658.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. de Bot ST,
    2. van den Elzen RTM,
    3. Mensenkamp AR, et al.
    Hereditary spastic paraplegia due to SPAST mutations in 151 Dutch patients: new clinical aspects and 27 novel mutations. J Neurol Neurosurg Psychiatry. 2010;81(10):1073-1078.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Rattay TW,
    2. Boldt A,
    3. Völker M, et al
    . Non-motor symptoms are relevant and possibly treatable in hereditary spastic paraplegia type 4 (SPG4). J Neurol. 2020;267(2):369-379.
    OpenUrl
  47. 47.↵
    1. Jacinto-Scudeiro LA,
    2. Dariva Machado G,
    3. Ayres A, et al.
    Are cognitive changes in hereditary spastic paraplegias restricted to complicated forms? Front Neurol. 2019;10:508.
    OpenUrl
  48. 48.↵
    1. Fink JK
    . Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 2013;126(3):307-328.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Pensato V,
    2. Castellotti B,
    3. Gellera C, et al
    . Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. Brain. 2014;137(pt 7):1907-1920.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Orlacchio A,
    2. Kawarai T,
    3. Totaro A, et al
    . Hereditary spastic paraplegia: clinical genetic study of 15 families. Arch Neurol. 2004;61(6):849-855.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Scuderi C,
    2. Fichera M,
    3. Calabrese G, et al.
    Posterior fossa abnormalities in hereditary spastic paraparesis with spastin mutations. J Neurol Neurosurg Psychiatry. 2008;80(4):440-443.
    OpenUrl
  52. 52.↵
    1. Alber B,
    2. Pernauer M,
    3. Schwan A, et al
    . Spastin related hereditary spastic paraplegia with dysplastic corpus callosum. J Neurol Sci. 2005;236(1-2):9-12.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Servelhere KR,
    2. Rezende TJR,
    3. de Lima FD, et al
    . Brain damage and gene expression across hereditary spastic paraplegia subtypes. Mov Disord. 2021;36(7):1644-1653.
    OpenUrl
  54. 54.↵
    1. Lindig T,
    2. Bender B,
    3. Hauser TK, et al
    . Gray and white matter alterations in hereditary spastic paraplegia type SPG4 and clinical correlations. J Neurol. 2015;262(8):1961-1971.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Wood JD,
    2. Landers JA,
    3. Bingley M, et al
    . The microtubule-severing protein Spastin is essential for axon outgrowth in the zebrafish embryo. Hum Mol Genet. 2006;15(18):2763-2771.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Rodrigues R,
    2. Silva R,
    3. Branco M, et al
    . Determinants of age at onset in a Portuguese cohort of autosomal dominant spastic paraplegia. J Neurol Sci. 2020;410:116646.
    OpenUrl
  57. 57.↵
    1. Lan MY,
    2. Chang YY,
    3. Yeh TH, et al
    . High frequency of SPG4 in Taiwanese families with autosomal dominant hereditary spastic paraplegia. BMC Neurol. 2014;14:216.
    OpenUrl
  58. 58.↵
    1. Fonknechten N,
    2. Mavel D,
    3. Byrne P, et al
    . Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet. 2000;9(4):637-644.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Erfanian Omidvar M,
    2. Torkamandi S,
    3. Rezaei S, et al.
    Genotype–phenotype associations in hereditary spastic paraplegia: a systematic review and meta-analysis on 13,570 patients. J Neurol. 2021;268(8):2065-2082.
    OpenUrl
  60. 60.↵
    1. Lemos C,
    2. Coelho T,
    3. Alves-Ferreira M, et al
    . Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85(3):326-330.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Proukakis C,
    2. Moore D,
    3. Labrum R,
    4. Wood NW,
    5. Houlden H
    . Detection of novel mutations and review of published data suggests that hereditary spastic paraplegia caused by spastin (SPAST) mutations is found more often in males. J Neurol Sci. 2011;306(1-2):62-65.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Siow S-F,
    2. Cameron Smail R,
    3. Ng K,
    4. Kumar KR,
    5. Sue CM
    . Motor evoked potentials in hereditary spastic paraplegia—a systematic review. Front Neurol. 2019;10:967.
    OpenUrl
  63. 63.↵
    1. Kadnikova VA,
    2. Rudenskaya GE,
    3. Stepanova AA,
    4. Sermyagina IG,
    5. Ryzhkova OP
    . Mutational spectrum of spast (Spg4) and Atl1 (Spg3a) genes in russian patients with hereditary spastic paraplegia. Sci Rep. 2019;9:14412.
    OpenUrl
  64. 64.↵
    1. Svenson IK,
    2. Kloos MT,
    3. Gaskell PC, et al
    . Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations. Neurogenetics. 2004;5(3):157-164.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. McDermott CJ,
    2. Burness CE,
    3. Kirby J, et al
    . Clinical features of hereditary spastic paraplegia due to spastin mutation. Neurology. 2006;67(1):45-51.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Sardina F,
    2. Pisciottani A,
    3. Ferrara M, et al
    . Spastin recovery in hereditary spastic paraplegia by preventing neddylation-dependent degradation. Life Sci Alliance. 2020;3(12):e202000799.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Alert Me

Advertisement